Nobel Laureate Joins AI Rival
Nobel Laureate John Jumper Departs Google DeepMind to Join AI Rival Anthropic
Key Points
In his X announcement, Jumper added that Demis Hassabis “took a real chance letting me lead the AlphaFold team just six months after finishing my PhD,” saying “GDM is a special place” and that the “entire GDM team taught me so much about how to do great science.”
AlphaFold’s real-world footprint is described as a large public resource: it is “offering over 200 million protein structure predictions,” which “cuts months and even years from the research process.”
DeepMind CEO Demis Hassabis emphasized AlphaFold’s broader AI-for-medicine implications in his own X post, writing: “What we achieved with AlphaFold changed the world… lighting the way for how AI can benefit humanity.”
Bloomberg reported that Jumper’s departure adds to strains on Google’s race to build the most powerful AI models—alongside competitors including Anthropic, OpenAI, and Elon Musk’s SpaceX—and said “Google has struggled to sell AI coding tools to businesses,” citing former employees.
John Jumper, the Nobel Prize-winning scientist behind AlphaFold, is leaving Google DeepMind after nearly nine years to join Anthropic, Bloomberg reported on June 18. Jumper said he plans to spend time "recharging" before starting at the AI startup. He did not say what his role there will be.
Jumper co-led AlphaFold, the AI system that predicts the 3D shape of proteins from their chemical building blocks. That work earned him and DeepMind CEO Demis Hassabis a share of the 2024 Nobel Prize in Chemistry. The move is one of the most high-profile talent shifts in AI history.
AlphaFold Reshaped Biology in Just Nine Years
Jumper joined DeepMind in 2017, just six months after finishing his PhD in Chemistry at the University of Chicago. He went on to lead the AlphaFold team. In December 2020, AlphaFold 2 cracked a 50-year-old scientific puzzle: predicting the exact 3D shape a protein will fold into. Scientists had struggled with that problem for decades.
By July 2022, DeepMind had used AlphaFold to predict structures for more than 200 million proteins and made them all free to access. Over 2 million researchers have used the database, according to Bloomberg. Hassabis wrote on X: "What we achieved with AlphaFold changed the world… lighting the way for how AI can benefit humanity." That database, Hassabis said, cuts "months and even years" from the research process.
Jumper Leaves With Praise for DeepMind, Heads to Anthropic
Jumper announced his exit on X, thanking DeepMind with warm words. "Demis took a real chance letting me lead the AlphaFold team just six months after finishing my PhD," he wrote. He called DeepMind "a special place" and said the team "taught me so much about how to do great science."
His next stop is Anthropic, the AI startup founded by former OpenAI researchers and led by Dario Amodei. Anthropic has raised $7 billion in funding, including money from Amazon and Google itself, according to Bloomberg. Jumper has not said what he will work on there.
Google Faces Growing Brain Drain to AI Rivals
Jumper's exit is the latest in a string of high-profile departures from Google DeepMind to startups. Bloomberg reported that his departure adds strain to Google's effort to build the most powerful AI models. Google is competing against Anthropic, OpenAI, and Elon Musk's xAI, among others.
Google has also "struggled to sell AI coding tools to businesses," Bloomberg reported, citing former employees. Analysts say losing a Nobel laureate sharpens that narrative. Anthropic, on the other hand, gets a major credibility boost. Recruiting a Nobel Prize winner signals to investors that the firm can attract the very best talent in the world.
Jumper's Arrival Could Push Anthropic Into Scientific AI
Anthropic is best known for Claude, its large language model. But Jumper's hire suggests the company may be moving into a new area: AI built for science. That could mean models that reason about chemistry, biology, and drug discovery — fields where AlphaFold already proved AI can do extraordinary things.
DeepMind's commercial drug-discovery arm, Isomorphic Labs, has been a key part of Google's bet on biological AI. If Anthropic builds a competing effort around Jumper, it could challenge Google in a drug discovery market worth hundreds of billions of dollars. For now, Jumper says he is taking a break first — and the AI world is watching closely to see what comes next.
Sentiment
Mostly PositivePublishers
19
Articles
28
Reach
47
